Delcath Systems, Inc. (DCTH) shareholders
Close on Nov 17, 2026Market cap $672.12MP/E 1937.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rosalind Advisors, Inc. Joint filing with Salamon Steven A J (9.90%), Aharon Gil (9.90%) | 6,692,491 | 9.90% | 13D (active) amendment | Oct 13, 2026 |
| BlackRock Portfolio Management LLC | 2,180,493 | 6.30% | 13G (passive) | Sep 30, 2026 |
| BlackRock, Inc. | 1,836,121 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Daniel Kaufman | 1,766,432 | 5.08% | 13G (passive) | Mar 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DCTH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,300,389 | 9.51% | $41.55M | – | 15.44% |
| BlackRock, Inc. | 2,706,802 | 7.80% | $34.08M | +922,336 | 0.00% |
| Vanguard Capital Management LLC | 1,221,247 | 3.52% | $15.38M | −108,041 | 0.00% |
| Propel Bio Management, LLC | 871,460 | 2.51% | $10.97M | −108,238 | 5.74% |
| Geode Capital Management, LLC | 733,115 | 2.11% | $9.23M | +41,084 | 0.00% |
| State Street Corp | 679,280 | 1.96% | $8.55M | +14,852 | 0.00% |
| Algert Global LLC | 580,708 | 1.67% | $7.31M | +434,975 | 0.09% |
| Millennium Management LLC | 566,371 | 1.63% | $7.13M | −21,684 | 0.00% |
| Divisadero Street Capital Management, LP | 499,796 | 1.44% | $6.29M | – | 0.14% |
| Morgan Stanley | 407,983 | 1.18% | $5.14M | +22,459 | 0.00% |
| ExodusPoint Capital Management, LP | 359,884 | 1.04% | $4.53M | +323,916 | 0.03% |
| Private Wealth Advisors, LLC | 310,863 | 0.90% | $3.91M | −280,661 | 1.00% |
| Simplify Asset Management Inc. | 264,770 | 0.76% | $3.33M | +3,644 | 0.05% |
| Northern Trust Corp | 252,108 | 0.73% | $3.17M | +245 | 0.00% |
| Goldman Sachs Group Inc | 250,312 | 0.72% | $3.15M | −38,819 | 0.00% |
| ADAR1 Capital Management, LLC | 224,385 | 0.65% | $2.83M | – | 0.13% |
| Marshall Wace, Llp | 218,963 | 0.63% | $2.76M | +27,333 | 0.00% |
| Dimensional Fund Advisors LP | 210,298 | 0.61% | $2.65M | New | 0.00% |
| Kennedy Capital Management LLC | 204,143 | 0.59% | $2.57M | −3,780 | 0.05% |
| Vanguard Portfolio Management LLC | 193,448 | 0.56% | $2.44M | +15,412 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 120 | 17M | 50.2% | 20 / 48 | 26 / 20 | 3M | 2M |
| Q1 2026 | 121 | 16M | 47.0% | 27 / 37 | 36 / 23 | 4M | 3M |
| Q4 2025 | 119 | 17M | 49.4% | 18 / 42 | 36 / 19 | 2M | 3M |
| Q3 2025 | 124 | 18M | 52.1% | 31 / 39 | 36 / 24 | 4M | 4M |
| Q2 2025 | 117 | 18M | 52.9% | 49 / 39 | 19 / 29 | 7M | 4M |
| Q1 2025 | 98 | 15M | 43.5% | 20 / 41 | 26 / 12 | 5M | 4M |
| Q4 2024 | 90 | 14M | 39.4% | 30 / 33 | 13 / 8 | 5M | 1M |
| Q3 2024 | 69 | 10M | 30.0% | 23 / 17 | 14 / 5 | 2M | 2M |
| Q2 2024 | 52 | 10M | 30.2% | 19 / 17 | 10 / 3 | 3M | 2M |
| Q1 2024 | 36 | 9M | 24.8% | 2 / 13 | 12 / 8 | 3M | 1M |
| Q4 2023 | 42 | 7M | 19.9% | 11 / 19 | 5 / 7 | 3M | 4M |
| Q3 2023 | 38 | 7M | 20.4% | 11 / 12 | 8 / 4 | 3M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
112 funds held DCTH in Q2 2026, 62% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DCTH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 889,410 | 2.56% | $11.20M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 757,196 | 2.18% | $9.53M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 314,275 | 0.91% | $3.84M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 304,809 | 0.88% | $3.84M | 0.00% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 261,126 | 0.75% | $3.29M | 4.26% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 229,809 | 0.66% | $2.89M | 0.02% | Jun 30, 2026 |
| North Square Dynamic Small Cap Fund | 192,363 | 0.55% | $2.07M | 0.26% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 154,942 | 0.45% | $1.67M | 0.01% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 141,229 | 0.41% | $1.78M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 140,170 | 0.40% | $1.51M | 0.00% | May 31, 2026 |
| Small Cap Equity Fund | 122,700 | 0.35% | $1.54M | 0.15% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 100,899 | 0.29% | $1.09M | 0.02% | May 29, 2026 |
| iShares Micro-Cap ETF | 96,698 | 0.28% | $1.22M | 0.08% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Growth Fund | 73,405 | 0.21% | $924.17K | 0.11% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 70,457 | 0.20% | $860.98K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Gerard J. Michel | CHIEF EXECUTIVE OFFICER, Director | 342,034 | 0.99% | Mar 3, 2026 |
| Sandra Pennell | Chief Financial Officer | 77,018 | 0.22% | Mar 6, 2026 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 74,330 | 0.21% | Feb 18, 2026 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 168,882 | 0.49% | Feb 18, 2026 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 18,582 | 0.05% | Feb 18, 2026 |
| Martha S. Rook | CHIEF OPERATING OFFICER | – | – | Feb 18, 2026 |
| Bridget A. Martell | Director | 0 | – | Nov 13, 2026 |
| Rosalind Advisors, Inc. | Director | 3,389,593 | 9.77% | Oct 14, 2026 |
| Gil Aharon | Director | 4,483,178 | 12.92% | Oct 14, 2026 |
| Steven A. J. Salamon | Director | 4,534,493 | 13.07% | Oct 14, 2026 |
| John Richard Sylvester | Director | 14,936 | 0.04% | May 14, 2026 |
| Elizabeth Czerepak | Director | – | – | May 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bridget A. Martell Director | Nov 12, 2026 | Sale | −1,930 | $22.26 | $42.96K | 0 |
| Bridget A. Martell Director | Nov 12, 2026 | Sale | −20,570 | $21.66 | $445.55K | 1,930 |
| Bridget A. Martell Director | Nov 12, 2026 | Option exercise | +22,500 | $7.85 | $176.63K | 22,500 |
| Rosalind Advisors, Inc. Director | Oct 13, 2026 | Other | −27,502 | – | – | 3,389,593 |
| Rosalind Advisors, Inc. Director | Oct 13, 2026 | Conversion | +3,627 | – | – | 3,417,095 |
| Sandra Pennell Chief Financial Officer | Mar 6, 2026 | Buy | +5,533 | $9.04 | $50.02K | 77,018 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Mar 2, 2026 | Buy | +11,200 | $8.96 | $100.35K | 342,034 |
| John Richard Sylvester Director | Nov 21, 2025 | Buy | +4,386 | $8.89 | $38.99K | 14,936 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Nov 11, 2025 | Buy | +11,500 | $8.53 | $98.09K | 330,834 |
| Vojo Vukovic CHIEF MEDICAL OFFICER | Jun 12, 2025 | Option exercise | +42,000 | $4.78 | $200.76K | 168,882 |
| Gil Aharon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | May 5, 2025 | Option exercise | +400,000 | $10.00 | $4.00M | 3,413,468 |
| Steven A. J. Salamon Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Rosalind Advisors, Inc. Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Gil Aharon Director | Dec 24, 2024 | Conversion | +250,000 | $10.00 | $2.50M | 3,013,468 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Oct 22, 2024 | Option exercise | +16,666 | $6.00 | $100.00K | 319,334 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,681,271 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,732,586 |
| Steven A. J. Salamon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,732,586 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,681,271 |
| Gil Aharon Director | Apr 18, 2024 | Option exercise | +619,946 | $0.01 | $6.20K | 2,763,468 |
| Gil Aharon Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,763,468 |
| Rosalind Advisors, Inc. Director | Apr 18, 2024 | Conversion | +991,615 | – | – | 2,763,468 |
| Rosalind Advisors, Inc. Director | Apr 18, 2024 | Option exercise | +619,946 | $6199.46 | $3.84B | 2,763,468 |
| Steven A. J. Salamon Director | Mar 19, 2024 | Buy | +26,882 | $3.72 | $100.00K | 1,121,025 |
| Gil Aharon Director | Mar 19, 2024 | Buy | +26,882 | $3.72 | $100.00K | 1,069,710 |
| Sandra Pennell SVP OF FINANCE, PFO AND PAO | Mar 19, 2024 | Award | +26,881 | $3.72 | $100.00K | 61,052 |
| Gerard J. Michel CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2024 | Award | +40,323 | $3.72 | $150.00K | 302,668 |
| David L. Hoffman GEN'L COUNSEL, CCO & SECY | Mar 19, 2024 | Award | +20,161 | $3.72 | $75.00K | 74,330 |
| Vojo Vukovic CHIEF MEDICAL OFFICER | Mar 19, 2024 | Award | +26,882 | $3.72 | $100.00K | 126,882 |
| Kevin Muir GM INTERVENTIONAL ONCOLOGY | Mar 19, 2024 | Award | +13,441 | $3.72 | $50.00K | 18,582 |
| Vojo Vukovic Chief Medical Officer | Dec 12, 2023 | Buy | +40,000 | $3.00 | $120.00K | 100,000 |
| Gerard J. Michel Chief Executive Officer, Director | Dec 8, 2023 | Buy | +34,000 | $2.94 | $99.96K | 262,345 |
| Sandra Pennell SVP of Finance, PFO and PAO | Nov 17, 2023 | Buy | +30,000 | $2.43 | $72.90K | 30,000 |
| Rosalind Advisors, Inc. Director | Nov 17, 2023 | Buy | +100,000 | $2.40 | $240.00K | 1,038,828 |
| David L. Hoffman See Remarks | Nov 16, 2023 | Buy | +40,000 | $2.48 | $99.20K | 40,000 |
| Vojo Vukovic Chief Medical Officer | Nov 16, 2023 | Buy | +60,000 | $2.48 | $148.80K | 60,000 |
| John Purpura Chief Operating Officer | Oct 13, 2023 | Buy | +14,505 | $3.44 | $49.90K | 41,526 |
| John Richard Sylvester Director | Aug 21, 2023 | Buy | +10,550 | $4.80 | $50.64K | 10,550 |
| Gerard J. Michel Chief Executive Officer, Director | Aug 18, 2023 | Option exercise | +31,110 | $4.50 | $140.00K | 228,345 |
| Gerard J. Michel Chief Executive Officer, Director | Mar 29, 2023 | Buy | +19,646 | $4.84 | $95.09K | 197,235 |
| Steven A. J. Salamon Director | Dec 14, 2022 | Buy | +15,215 | $3.62 | $55.08K | 455,315 |
| Rosalind Advisors, Inc. Director | Dec 14, 2022 | Buy | +15,215 | $3.62 | $55.08K | 459,315 |
| Gerard J. Michel Chief Executive Officer, Director | Dec 13, 2022 | Buy | +51,725 | $2.90 | $150.00K | 177,589 |
| Gerard J. Michel Chief Executive Officer, Director | Jul 20, 2022 | Buy | +62,814 | $3.98 | $250.00K | 125,864 |
| John Purpura Chief Operating Officer | May 16, 2022 | Buy | +3,300 | $4.61 | $15.21K | 27,021 |
| Steven A. J. Salamon Director | May 13, 2022 | Buy | +5,000 | $5.03 | $25.15K | 440,100 |
| Steven A. J. Salamon Director | May 12, 2022 | Buy | +6,000 | $4.90 | $29.40K | 29,424 |
| Rosalind Advisors, Inc. Director | Apr 19, 2022 | Buy | +1,600 | $6.25 | $10.00K | 433,100 |
| Steven A. J. Salamon Director | Apr 19, 2022 | Buy | +1,600 | $6.25 | $10.00K | 429,100 |
| Gil Aharon Director | Apr 18, 2022 | Buy | +2,000 | $6.35 | $12.70K | 404,000 |
| Rosalind Advisors, Inc. Director | Apr 18, 2022 | Buy | +2,000 | $6.35 | $12.70K | 431,500 |
| Gerard J. Michel See Remarks, Director | Apr 18, 2022 | Buy | +1,800 | $6.37 | $11.47K | 63,050 |
| Gerard J. Michel See Remarks, Director | Apr 18, 2022 | Buy | +200 | $6.34 | $1.27K | 61,250 |
| Steven A. J. Salamon Director | Apr 13, 2022 | Buy | +1,500 | $6.45 | $9.68K | 427,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Delcath Systems's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,481 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Roger G. Stoll Phd Retired | Jul 9, 2024 | 1,000 | $7.29K | Jul 9, 2024 | Stock Options |
Congress trades
1 trade in Delcath Systems reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Roger W. Marshall KS01 · child | Sold | Jun 9, 2017 | $1K–15K | Aug 6, 2018 423 days late |
See a number that looks wrong?